Diamond, Don J.

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentImmunotherapy and Immune Responses

Cited by 66

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

Hardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 45

Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

Yuan, Y., Kos, F. J., He, T.-F., Yin, H. H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R. K., et al. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 23

Overcoming immunosuppression to enhance a p53MVA vaccine

Hardwick, N., Chung, V., Cristea, M., Ellenhorn, J. D., & Diamond, D. J. (2014) · OncoImmunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 11